Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cellmediated lysis in multiple myeloma

Oncotarget

Volumn 8, Issue 4, 2017, Pages 5954-5964

  Niu, Chao ^a   Jin, Haofan ^a   Li, Min ^a   Zhu, Shan ^a   Zhou, Lei ^a   Jin, Feng ^a,b   Zhou, Yulai ^b   Xu, Dongsheng ^a   Xu, Jianting ^a   Zhao, Lianjing ^a   Hao, Shanshan ^a,c   Li, Wei ^a   Cui, Jiuwei ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b JILIN UNIVERSITY   (China)

^c Taian Central Hospital   (China)

Author keywords

Bortezomib; Gamma delta T cells; Multiple myeloma; Natural killer cells

Indexed keywords

BORTEZOMIB; CELL PROTEIN; MESSENGER RNA; NATURAL KILLER CELL RECEPTOR NKG2D; NECTIN 2; PROTEIN DNAM 1; PROTEIN MICA; PROTEIN MICB; PROTEIN PVR; RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD226 ANTIGEN; KLRK1 PROTEIN, HUMAN; LIGAND; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; T LYMPHOCYTE ANTIGEN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL VIABILITY; CHEMOSENSITIZATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; DEGRANULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NATURAL KILLER CELL; PROTEIN EXPRESSION; CELL SURVIVAL; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION REGULATION; INTRAEPITHELIAL LYMPHOCYTE; LYMPHOCYTE ACTIVATION; METABOLISM; MULTIMODALITY CANCER THERAPY; TRANSPLANTATION; TUMOR CELL LINE; UPREGULATION;

AGED; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; ANTINEOPLASTIC AGENTS; BORTEZOMIB; CELL LINE, TUMOR; CELL SURVIVAL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRAEPITHELIAL LYMPHOCYTES; KILLER CELLS, NATURAL; LIGANDS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; UP-REGULATION;

EID: 85010712127     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13979     Document Type: Article

References (40)

1. Fuchs O. Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma. Cardiovasc Hematol Disord Drug Targets. 2013; 13:16-34.
2. Anderson KC. Bortezomib therapy for myeloma. Curr Hematol Rep. 2004; 3:65.
3. Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, Sayers TJ, Hudig D, Murphy WJ. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol. 2008; 180:163-170.
4. Rollig C, Knop S, Bornhauser M. Multiple myeloma. Lancet. 2015; 385:2197-2208.
5. Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. Blood. 2015; 125:3076-3084.
6. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012; 26:149-157.
7. Zou Y, Ma X, Yu H, Hu C, Fan L, Ran X. Carfilzomib/pomalidomide single-agent or in combination with other agents for the management of relapsed/refractory multiple myeloma: a meta-analysis of 37 trials. Oncotarget. 2016. doi: 10.18632/oncotarget.10768. [Epub ahead of print].
8. Campbell KS, Hasegawa J. Natural killer cell biology: an update and future directions. The Journal of allergy and clinical immunology. 2013; 132:536-544.
9. Meraviglia S, Lo Presti E, Dieli F, Stassi G. gammadelta T cell-based anticancer immunotherapy: progress and possibilities. Immunotherapy. 2015; 7:949-951.
10. Guo Y, Feng X, Jiang Y, Shi X, Xing X, Liu X, Li N, Fadeel B, Zheng C. PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells. Oncotarget. 2016; 7:48360-48374. doi: 10.18632/oncotarget.10235.
11. Kabelitz D. Human gammadelta T cells: From a neglected lymphocyte population to cellular immunotherapy: A personal reflection of 30years of gammadelta T cell research. Clin Immunol. 2016.
12. Rezvani K, Rouce RH. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer. Frontiers in immunology. 2015; 6:578.
13. Fisher JP, Heuijerjans J, Yan M, Gustafsson K, Anderson J. gammadelta T cells for cancer immunotherapy: A systematic review of clinical trials. Oncoimmunology. 2014; 3:e27572.
14. Burjanadze M, Condomines M, Reme T, Quittet P, Latry P, Lugagne C, Romagne F, Morel Y, Rossi JF, Klein B, Lu ZY. In vitro expansion of gamma delta T cells with antimyeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Br J Haematol. 2007; 139:206-216.
15. Knight A, Mackinnon S, Lowdell MW. Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells. Cytotherapy. 2012; 14:1110-1118.
16. Garg TK, Szmania SM, Khan JA, Hoering A, Malbrough PA, Moreno-Bost A, Greenway AD, Lingo JD, Li X, Yaccoby S, Suva LJ, Storrie B, Tricot G, et al. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica. 2012; 97:1348-1356.
17. Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, et al. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. Journal of immunotherapy. 2015; 38:24-36.
18. Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, Starling GC, Ciarlariello D, Bhaskar S, Briercheck EL, Hughes T, Yu J, Rice A, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013; 62:1841-1849.
19. Balasa B, Yun R, Belmar NA, Fox M, Chao DT, Robbins MD, Starling GC, Rice AG. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-alpha pathways. Cancer Immunol Immunother. 2015; 64:61-73.
20. Lagrue K, Carisey A, Morgan DJ, Chopra R, Davis DM. Lenalidomide augments actin remodeling and lowers NKcell activation thresholds. Blood. 2015; 126:50-60.
21. Yang G, Gao M, Zhang Y, Kong Y, Gao L, Tao Y, Han Y, Wu H, Meng X, Xu H, Zhan F, Wu X, Shi J. Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I. Oncotarget. 2015; 6:26982-26994. doi: 10.18632/oncotarget.4831.
22. Bryceson YT, Chiang SC, Darmanin S, Fauriat C, Schlums H, Theorell J, Wood SM. Molecular mechanisms of natural killer cell activation. Journal of innate immunity. 2011; 3:216-226.
23. Van Acker HH, Anguille S, Van Tendeloo VF, Lion E. Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy. Oncoimmunology. 2015; 4:e1021538.
24. Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE, Storrie B, Mulder A, Shaughnessy JD, Jr., Barlogie B, van Rhee F. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood. 2008; 111:1309-1317.
25. Kim HS. A multifaceted approach targeting NK cells for better treatment of cancer: focus on hematological malignancies. Blood research. 2015; 50:189-191.
26. Niu C, Jin H, Li M, Xu J, Xu D, Hu J, He H, Li W, Cui J. In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokineinduced killer cells, and gamma-delta T cells. BMC Immunol. 2015; 16:61.
27. Schwartz R, Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology. 2004; 18:14-21.
28. Moreau P, Karamanesht, II, Domnikova N, Kyselyova MY, Vilchevska KV, Doronin VA, Schmidt A, Hulin C, Leleu X, Esseltine DL, Venkatakrishnan K, Skee D, et al. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clinical pharmacokinetics. 2012; 51:823-829.
29. Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE, Chapoval AI. Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood. 2010; 116:1726-1733.
30. Braza MS, Klein B. Anti-tumour immunotherapy with Vgamma9Vdelta2 T lymphocytes: from the bench to the bedside. Br J Haematol. 2013; 160:123-132.
31. Han W, Zhang X, Jia Z, He J, Chao H, Yang J, Xiao R, Lu X. Study of NK cells dysfunction in multiple myeloma patients. Zhonghua Xue Ye Xue Za Zhi. 2015; 36:922-925.
32. Castella B, Foglietta M, Sciancalepore P, Rigoni M, Coscia M, Griggio V, Vitale C, Ferracini R, Saraci E, Omede P, Riganti C, Palumbo A, Boccadoro M, et al. Anergic bone marrow Vgamma9Vdelta2 T cells as early and long-lasting markers of PD-1-targetable microenvironmentinduced immune suppression in human myeloma. Oncoimmunology. 2015; 4:e1047580.
33. Ponzetta A, Benigni G, Antonangeli F, Sciume G, Sanseviero E, Zingoni A, Ricciardi MR, Petrucci MT, Santoni A, Bernardini G. Multiple Myeloma Impairs Bone Marrow Localization of Effector Natural Killer Cells by Altering the Chemokine Microenvironment. Cancer Res. 2015; 75:4766-4777.
34. Pellom ST, Jr., Dudimah DF, Thounaojam MC, Sayers TJ, Shanker A. Modulatory effects of bortezomib on host immune cell functions. Immunotherapy. 2015; 7:1011-1022.
35. Shanker A, Pellom ST, Jr., Dudimah DF, Thounaojam MC, de Kluyver RL, Brooks AD, Yagita H, McVicar DW, Murphy WJ, Longo DL, Sayers TJ. Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity. Cancer Res. 2015; 75:5260-5272.
36. Seki N, Toh U, Sayers TJ, Fujii T, Miyagi M, Akagi Y, Kusukawa J, Kage M, Shirouzu K, Yamana H. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways. Mol Cancer Ther. 2010; 9:1842-1851.
37. Bryceson YT, Rudd E, Zheng C, Edner J, Ma D, Wood SM, Bechensteen AG, Boelens JJ, Celkan T, Farah RA, Hultenby K, Winiarski J, Roche PA, et al. Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood. 2007; 110:1906-1915.
38. Kang L, Sun J, Wen X, Cui J, Wang G, Hoffman AR, Hu JF, Li W. Aberrant allele-switch imprinting of a novel IGF1R intragenic antisense non-coding RNA in breast cancers. Eur J Cancer. 2015; 51:260-270.
39. Shi X, Li M, Cui M, Niu C, Xu J, Zhou L, Li W, Gao Y, Kong W, Cui J, Hu J, Jin H. Epigenetic suppression of the antitumor cytotoxicity of NK cells by histone deacetylase inhibitor valproic acid. Am J Cancer Res. 2016; 6:600-614.
40. Li T, Chen H, Li W, Cui J, Wang G, Hu X, Hoffman AR, Hu J. Promoter histone H3K27 methylation in the control of IGF2 imprinting in human tumor cell lines. Hum Mol Genet. 2014; 23:117-128.